Todd F. Hatchette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Todd F. Hatchette has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Jason J. LeBlanc
Canadian Center for Vaccinology, Dalhousie, Halifax, NS, Canada Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, NS, Canada
2 shared publications- Jason J. LeBlanc
Department of Microbiology and Immunology, Dalhousie University
2 shared publications - Shelly A. McNeil
Canadian Center for Vaccinology, IWK Health, Nova Scotia Health, Dalhousie University , Halifax, Nova Scotia
2 shared publications Alberto Severini
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
1 shared publicationAngela Brewer
Research Institute of the McGill University Health Centre, Montréal, QC, Canada
1 shared publicationAngela Mask
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 24 (1) , 118-121
High Seroprevalence of Jamestown Canyon Virus among Deer and Humans, Nova Scotia, Canada
Using residual serum samples from Nova Scotia, Canada, we found that 87.8% of tested deer and an estimated 20.6% of the human population were infected with Jamestown Canyon virus. Human seropositivity reached 48.2% in 1 region. This virus may be an underrecognized cause of disease in Nova Scotia.
- 1 January 2018
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 24 (1) , 118-121
Open AccessHigh Seroprevalence of Jamestown Canyon Virus among Deer and Humans, Nova Scotia, Canada
Using residual serum samples from Nova Scotia, Canada, we found that 87.8% of tested deer and an estimated 20.6% of the human population were infected with Jamestown Canyon virus. Human seropositivity reached 48.2% in 1 region. This virus may be an underrecognized cause of disease in Nova Scotia.
- 1 January 2017
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 24 (1)
Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200
The BioPlex 2200 (Bio-Rad Laboratories, Hercules, Ca) is a rapid, automated platform, which can screen large numbers of specimens for antibodies to measles, mumps, rubella and varicella. Although approved for producing qualitative results, in this study we have validated the test (off-label) to allow reporting of quantitative results. To do this, we used the 3rd anti-measles WHO standard to generate a calibration curve that allowed relative fluorescence intensity to be translated into quantitative antibody titer (Antibody Units/mL (AU/mL)). Results from the BioPlex 2200 and the reference plaque reduction neutralization test (PRNT) exhibited a reasonable correlation following an exponential function, but correlation was poor in low titer samples. Using a Receiver Operating Characteristics analysis an equivocal zone for the BioPlex 2200 was established between ≥0.13 AU/mL and <1.10 AU/mL to achieve 100% specificity (83.2-100 95%CI) and 100% sensitivity (93.5 – 100 95%CI) versus PRNT. By determining an equivocal range requiring confirmation by PRNT, we can avoid underestimating levels of immunity through false negative results and optimize methods for sero-epidemiological studies.
- 1 January 2017
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 24 (1)
Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200
The BioPlex 2200 (Bio-Rad Laboratories, Hercules, Ca) is a rapid, automated platform, which can screen large numbers of specimens for antibodies to measles, mumps, rubella and varicella. Although approved for producing qualitative results, in this study we have validated the test (off-label) to allow reporting of quantitative results. To do this, we used the 3rd anti-measles WHO standard to generate a calibration curve that allowed relative fluorescence intensity to be translated into quantitative antibody titer (Antibody Units/mL (AU/mL)). Results from the BioPlex 2200 and the reference plaque reduction neutralization test (PRNT) exhibited a reasonable correlation following an exponential function, but correlation was poor in low titer samples. Using a Receiver Operating Characteristics analysis an equivocal zone for the BioPlex 2200 was established between ≥0.13 AU/mL and <1.10 AU/mL to achieve 100% specificity (83.2-100 95%CI) and 100% sensitivity (93.5 – 100 95%CI) versus PRNT. By determining an equivocal range requiring confirmation by PRNT, we can avoid underestimating levels of immunity through false negative results and optimize methods for sero-epidemiological studies.
- 1 March 2016
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 23 (3) , 236-242
Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories
Standardization of the hemagglutination inhibition (HAI) assay for influenza serology is challenging. Poor reproducibility of HAI results from one laboratory to another is widely cited, limiting comparisons between candidate vaccines in different clinical trials and posing challenges for licensing authorities. In this study, we standardized HAI assay materials, methods, and interpretive criteria across five geographically dispersed laboratories of a multidisciplinary influenza research network and then evaluated intralaboratory and interlaboratory variations in HAI titers by repeatedly testing standardized panels of human serum samples. Duplicate precision and reproducibility from comparisons between assays within laboratories were 99.8% (99.2% to 100%) and 98.0% (93.3% to 100%), respectively. The results for 98.9% (95% to 100%) of the samples were within 2-fold of all-laboratory consensus titers, and the results for 94.3% (85% to 100%) of the samples were within 2-fold of our reference laboratory data. Low-titer samples showed the greatest variability in comparisons between assays and between sites. Classification of seroprotection (titer ≥ 40) was accurate in 93.6% or 89.5% of cases in comparison to the consensus or reference laboratory classification, respectively. This study showed that with carefully chosen standardization processes, high reproducibility of HAI results between laboratories is indeed achievable.
- 1 March 2016
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 23 (3) , 236-242
Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories
Standardization of the hemagglutination inhibition (HAI) assay for influenza serology is challenging. Poor reproducibility of HAI results from one laboratory to another is widely cited, limiting comparisons between candidate vaccines in different clinical trials and posing challenges for licensing authorities. In this study, we standardized HAI assay materials, methods, and interpretive criteria across five geographically dispersed laboratories of a multidisciplinary influenza research network and then evaluated intralaboratory and interlaboratory variations in HAI titers by repeatedly testing standardized panels of human serum samples. Duplicate precision and reproducibility from comparisons between assays within laboratories were 99.8% (99.2% to 100%) and 98.0% (93.3% to 100%), respectively. The results for 98.9% (95% to 100%) of the samples were within 2-fold of all-laboratory consensus titers, and the results for 94.3% (85% to 100%) of the samples were within 2-fold of our reference laboratory data. Low-titer samples showed the greatest variability in comparisons between assays and between sites. Classification of seroprotection (titer ≥ 40) was accurate in 93.6% or 89.5% of cases in comparison to the consensus or reference laboratory classification, respectively. This study showed that with carefully chosen standardization processes, high reproducibility of HAI results between laboratories is indeed achievable.
- Open Access
- 18 July 2014
- Published by Springer Nature in Virology Journal
- Vol. 11 (1) , 129
Detection of circulating norovirus genotypes: hitting a moving target
Although national surveillance programs are in place to monitor norovirus epidemiology, the emergence of new strains and the genetic diversity among genotypes can be challenging for clinical laboratories. This study evaluated the analytical and clinical performance characteristics of one real-time RT-PCR and two end-point RT-PCRs commonly used in microbiology laboratories.
- 18 July 2014
- Published by Springer Nature in Virology Journal
- Vol. 11 (1) , 129
Open AccessDetection of circulating norovirus genotypes: hitting a moving target
Although national surveillance programs are in place to monitor norovirus epidemiology, the emergence of new strains and the genetic diversity among genotypes can be challenging for clinical laboratories. This study evaluated the analytical and clinical performance characteristics of one real-time RT-PCR and two end-point RT-PCRs commonly used in microbiology laboratories.
- 29 May 2014
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Canada Communicable Disease Report
- Vol. 40 (11) , 194-208
Lyme disease: clinical diagnosis and treatment
Lyme disease is an emerging zoonotic infection in Canada. As the Ixodes tick expands its range, more Canadians will be exposed to Borrelia burgdorferi, the bacterium that causes Lyme disease. To review the clinical diagnosis and treatment of Lyme disease for front-line clinicians. A literature search using PubMed and restricted to articles published in English between 1977 and 2014. Individuals in Lyme-endemic areas are at greatest risk, but not all tick bites transmit Lyme disease. The diagnosis is predominantly clinical. Patients with Lyme disease may present with early disease that is characterized by a "bull's eye rash", fever and myalgias or with early disseminated disease that can manifest with arthralgias, cardiac conduction abnormalities or neurologic symptoms. Late Lyme disease in North America typically manifests with oligoarticular arthritis but can present with a subacute encephalopathy. Antibiotic treatment is effective against Lyme disease and works best when given early in the infection. Prophylaxis with doxycyline may be indicated in certain circumstances. While a minority of patients may have persistent symptoms, evidence does not demonstrate that prolonged courses of antibiotics improve outcome. Clinicians need to be aware of the signs and symptoms of Lyme disease. Knowing the regions where Borrelia infection is endemic in North America is important for recognizing patients at risk and informing the need for treatment.
- 29 May 2014
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Canada Communicable Disease Report
- Vol. 40 (11) , 194-208
Lyme disease: clinical diagnosis and treatment
Lyme disease is an emerging zoonotic infection in Canada. As the Ixodes tick expands its range, more Canadians will be exposed to Borrelia burgdorferi, the bacterium that causes Lyme disease. To review the clinical diagnosis and treatment of Lyme disease for front-line clinicians. A literature search using PubMed and restricted to articles published in English between 1977 and 2014. Individuals in Lyme-endemic areas are at greatest risk, but not all tick bites transmit Lyme disease. The diagnosis is predominantly clinical. Patients with Lyme disease may present with early disease that is characterized by a "bull's eye rash", fever and myalgias or with early disseminated disease that can manifest with arthralgias, cardiac conduction abnormalities or neurologic symptoms. Late Lyme disease in North America typically manifests with oligoarticular arthritis but can present with a subacute encephalopathy. Antibiotic treatment is effective against Lyme disease and works best when given early in the infection. Prophylaxis with doxycyline may be indicated in certain circumstances. While a minority of patients may have persistent symptoms, evidence does not demonstrate that prolonged courses of antibiotics improve outcome. Clinicians need to be aware of the signs and symptoms of Lyme disease. Knowing the regions where Borrelia infection is endemic in North America is important for recognizing patients at risk and informing the need for treatment.
- Open Access
- 7 June 2013
- Published by Springer Nature in Virology Journal
- Vol. 10 (1) , 184
A cost effective real-time PCR for the detection of adenovirus from viral swabs
Compared to traditional testing strategies, nucleic acid amplification tests such as real-time PCR offer many advantages for the detection of human adenoviruses. However, commercial assays are expensive and cost prohibitive for many clinical laboratories. To overcome fiscal challenges, a cost effective strategy was developed using a combination of homogenization and heat treatment with an “in-house” real-time PCR. In 196 swabs submitted for adenovirus detection, this crude extraction method showed performance characteristics equivalent to viral DNA obtained from a commercial nucleic acid extraction. In addition, the in-house real-time PCR outperformed traditional testing strategies using virus culture, with sensitivities of 100% and 69.2%, respectively. Overall, the combination of homogenization and heat treatment with a sensitive in-house real-time PCR provides accurate results at a cost comparable to viral culture.
- 7 June 2013
- Published by Springer Nature in Virology Journal
- Vol. 10 (1) , 184
Open AccessA cost effective real-time PCR for the detection of adenovirus from viral swabs
Compared to traditional testing strategies, nucleic acid amplification tests such as real-time PCR offer many advantages for the detection of human adenoviruses. However, commercial assays are expensive and cost prohibitive for many clinical laboratories. To overcome fiscal challenges, a cost effective strategy was developed using a combination of homogenization and heat treatment with an “in-house” real-time PCR. In 196 swabs submitted for adenovirus detection, this crude extraction method showed performance characteristics equivalent to viral DNA obtained from a commercial nucleic acid extraction. In addition, the in-house real-time PCR outperformed traditional testing strategies using virus culture, with sensitivities of 100% and 69.2%, respectively. Overall, the combination of homogenization and heat treatment with a sensitive in-house real-time PCR provides accurate results at a cost comparable to viral culture.
- Open Access
- 1 January 2011
- Published by Springer Nature in International Journal for Equity in Health
- Vol. 10 (1) , 18
Barriers to gender-equitable HIV testing: going beyond routine screening for pregnant women in Nova Scotia, Canada
Women and men face different gender-based health inequities in relation to HIV, including HIV testing as well as different challenges in accessing HIV care, treatment and support programs and services when testing HIV-positive. In this article, we discuss the findings of a mixed methods study exploring the various individual and structural barriers and facilitators to HIV counselling and testing experienced among a sample of adult women and men living in Nova Scotia, Canada.
- 1 January 2011
- Published by Springer Nature in International Journal for Equity in Health
- Vol. 10 (1) , 18
Open AccessBarriers to gender-equitable HIV testing: going beyond routine screening for pregnant women in Nova Scotia, Canada
Women and men face different gender-based health inequities in relation to HIV, including HIV testing as well as different challenges in accessing HIV care, treatment and support programs and services when testing HIV-positive. In this article, we discuss the findings of a mixed methods study exploring the various individual and structural barriers and facilitators to HIV counselling and testing experienced among a sample of adult women and men living in Nova Scotia, Canada.
- Open Access
- 20 December 2010
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 183 (3) , 339-344
Infectious diarrhea: when to test and when to treat
Acute gastrointestinal illness is common. An estimated 1.3 episodes per person occur each year in Canada, which translates to more than 40 million incidents at an estimated cost of $3.7 billion annually.[1][1] Acute diarrhea is the second most common reason travellers returning from developing
- 20 December 2010
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 183 (3) , 339-344
Open AccessInfectious diarrhea: when to test and when to treat
Acute gastrointestinal illness is common. An estimated 1.3 episodes per person occur each year in Canada, which translates to more than 40 million incidents at an estimated cost of $3.7 billion annually.[1][1] Acute diarrhea is the second most common reason travellers returning from developing
- 3 September 2010
- Published by Springer Nature
- Vol. 697, 197-220
Mumps is Back: Why is Mumps Eradication Not Working?
- 3 September 2010
- Published by Springer Nature
- Vol. 697, 197-220
Mumps is Back: Why is Mumps Eradication Not Working?
- 1 December 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46 (4) , 381-383
Difficulty with mumps diagnosis: What is the contribution of mumps mimickers?
- 1 December 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46 (4) , 381-383
Difficulty with mumps diagnosis: What is the contribution of mumps mimickers?